A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7
Posted inHIV/AIDS Infectious Diseases news

A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7

In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage compared with currently licensed vaccines.
Evaluating the 23-Valent Pneumococcal Polysaccharide Vaccine for Cardiovascular Event Prevention: Insights from a Landmark Randomized Trial
Posted innews Public Health Respiratory

Evaluating the 23-Valent Pneumococcal Polysaccharide Vaccine for Cardiovascular Event Prevention: Insights from a Landmark Randomized Trial

A large randomized clinical trial demonstrated that the 23-valent pneumococcal polysaccharide vaccine (PPV23) did not significantly reduce fatal or nonfatal acute coronary syndrome and ischemic stroke among middle-aged adults at increased cardiovascular risk over seven years of follow-up.